| Literature DB >> 22085272 |
Roza Zandi1, Kai Xu, Hans S Poulsen, Jack A Roth, Lin Ji.
Abstract
The candidate tumor suppressor fragile histidine traid (FHIT) is frequently inactivated in small cell lung cancer (SCLC). Mutations in the p53 gene also occur in the majority of SCLC leading to the accumulation of the mutant protein. Here we evaluated the effect of FHIT gene therapy alone or in combination with the mutant p53-reactivating molecule, PRIMA-1(Met)/APR-246, in SCLC. Overexpression of FHIT by recombinant adenoviral vector (Ad-FHIT)-mediated gene transfer in SCLC cells inhibited their growth by inducing apoptosis and when combined with PRIMA-1(Met)/APR-246, a synergistic cell growth inhibition was achieved.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22085272 PMCID: PMC3372907 DOI: 10.3109/07357907.2011.626475
Source DB: PubMed Journal: Cancer Invest ISSN: 0735-7907 Impact factor: 2.176